

Dependent : Progression Free Survival		All	HR (univariable)
<b>Setting</b>	First Line	37 (42.0%)	-
	Second or Third Line	51 (58.0%)	1.80 (1.11-2.91, p= 0.016)
<b>Treatment</b>	Pembrolizumab	53 (60.2%)	-
	Nivolumab	35 (39.8%)	1.68 (1.05-2.69, p= 0.031)
<b>Tumor Burden</b>	≥ 115 mm	46 (52.3%)	-
	< 115 mm	42 (47.7%)	0.49 (0.31-0.78, p= 0.003)
<b>Liver Metastases</b>	Yes	71 (80.7%)	-
	No	17 (19.3%)	2.45 (1.38-4.37, p= 0.002)
<b>PDL1 Staning</b>	≥50%	44 (50.0%)	-
	<50%	44 (50.0%)	3.29 (1.96-5.50, p < 0.001)
<b>hsa.miR.625.5p</b>	Low	33 (37.5%)	-
	High	55 (62.5%)	2.04 (1.24-3.35, p= 0.005)